Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Other diagnosis

New Indication: Avelumab and Axitinib in Thymic Carcinoma

Ulas D. Bayraktar, MD

Bladder Cancer

New Indication: Durvalumab with CISplatin and Gemcitabine in Biliary Tract Cancers

Ulas D. Bayraktar, MD

Skin Cancer (Other than Melanoma)

New Indication: Neoadjuvant Cemiplimab for Cutaneous Squamous Cell Cancer

Ulas D. Bayraktar, MD

Diffuse Large B Cell Lymphoma

New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL

Ulas D. Bayraktar, MD

Chronic Lymphocytic Leukemia

New Reference: Zanubrutinib in CLL

Ulas D. Bayraktar, MD

Melanoma

New Drug: Tebentafusp in Metastatic Uveal Melanoma

Ulas D. Bayraktar, MD

Niraparib in prostate cancer

Non-Hodgkin Lymphoma Primary Mediastinal Large B-cell Lymphoma

New Reference: Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma

Ulas D. Bayraktar, MD

Niraparib in prostate cancer

Breast Cancer

New Indication: Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (MBC)

Ulas D. Bayraktar, MD

Niraparib in prostate cancer

Diffuse Large B Cell Lymphoma Non-Hodgkin Lymphoma

New Drug: Glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas

Ulas D. Bayraktar, MD

Other diagnosis

New Indication: Avelumab and Axitinib in Thymic Carcinoma

Single-arm, multicentre, phase 2 trial Had received at least one line of platinum-based chemotherapy Advanced stage thymoma or thymic carcinoma Avelumab 10 mg/kg/14 day and axitini

New Indication: Durvalumab with CISplatin and Gemcitabine in Biliary Tract Cancers

Double-blind, placebo-controlled, phase 3 study Untreated unresectable or metastatic biliary tract cancer Gemcitabine – cisplatin plus Durvalumab (341) or placebo (344)

Skin Cancer (Other than Melanoma)

New Indication: Neoadjuvant Cemiplimab for Cutaneous Squamous Cell Cancer

Phase 2, confirmatory, multicenter, nonrandomized study Resectable stage II, III, or IV (M0) cutaneous squamous-cell carcinoma Cemiplimab 350 mg/21 day (four doses) before surgery

Diffuse Large B Cell Lymphoma

New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL

Open-label, single-center, phase II study Previously untreated non-GCB DLBCL 60 patients Rituximab 375 mg/m2 (D1), lenalidomide 25 mg D(1-10), and ibrutinib 560 mg continuously (RL

Chronic Lymphocytic Leukemia

New Reference: Zanubrutinib in CLL

Open-label, multicentre, phase 3 study Untreated CLL or SLL Patients without del (17) (p13·1)  zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and pa

New Drug: Tebentafusp in Metastatic Uveal Melanoma

Open-label Phase III trial Untreated HLA-A*02:01-positive patients with metastatic uveal melanoma Tebentafusp or the investigator’s choice of therapy with single-agent pembrolizu

Non-Hodgkin LymphomaPrimary Mediastinal Large B-cell Lymphoma

New Reference: Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma

BLOOD, VOL 142, ISSUE 2, P141-145, JUL 2023 Zinzani Pier Luigi et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-1

New Indication: Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (MBC)

J Clin Oncol JUL 2023 Kalinsky Kevin et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in

Diffuse Large B Cell LymphomaNon-Hodgkin Lymphoma

New Drug: Glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf Reviewed by Elvin CHALABİYEV, MD on AUG 10, 2023

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag